Category Archives: Client News

Tonix Pharmaceuticals to Present Additional Clinical Results of Military-Related PTSD Study at the 2017 American Society of Clinical Psychopharmacology Annual Meeting

Important Retrospective Analyses from Phase 2 Study of US FDA-Designated Breakthrough Therapy TNX-102 SL in PTSD will be Highlighted NEW YORK, May 24, 2017 — Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to … Continue reading


Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD

Additional Important Findings Presented in Poster Session at the 72nd Annual Scientific Convention of the Society of Biological Psychiatry NEW YORK, May 22, 2017 — Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to … Continue reading


Avenue Therapeutics Receives Notice of Allowance for a New Patent Application Covering Methods of Administration for Intravenous Tramadol

NEW YORK, May 19, 2017 — Avenue Therapeutics, Inc. (“Avenue”), a Fortress Biotech (FBIO) Company, today announced that Notice of Allowance has now been received from the U.S. Patent and Trademark Office (USPTO) for a new patent application (U.S. Application … Continue reading


TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma

Three abstracts have been selected for oral presentation, including the positive results from the GENUINE Phase 3 study, and one for poster presentation NEW YORK, May 19, 2017 — TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that clinical abstracts featuring TG-1101 and TGR-1202 have … Continue reading


TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 22nd European Hematology Association Annual Congress

Presentations highlight triple combination therapies with the combination of TG-1101 and TGR-1202 as the backbone NEW YORK, May 18, 2017— TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that clinical abstracts featuring TG-1101 and TGR-1202 have been selected for presentation at the upcoming 22nd European Hematology … Continue reading


TG Therapeutics, Inc. Recaps Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology

Positive results from the GENUINE Phase 3 study to be featured in an oral presentation NEW YORK, May 17, 2017 — TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that clinical abstracts featuring TG-1101 and TGR-1202 have been selected for presentation at … Continue reading


Tonix Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Programs Update

Phase 3 HONOR Study of U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, Fully Funded and Currently Enrolling NEW YORK, May 15, 2017 — Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address … Continue reading


Tonix Pharmaceuticals to Present PTSD Clinical Data at the Society of Biological Psychiatry 72nd Annual Scientific Convention

Additional Results to be Presented from Phase 2 Study of US FDA-Designated Breakthrough Therapy, TNX-102 SL, in PTSD NEW YORK, May 11, 2017 — Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address … Continue reading


VERASTEM REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS

BOSTON— May 10, 2017– Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the first quarter ended March 31, 2017 and provided an overview of certain corporate … Continue reading


TG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2017 Financial Results

Investor Conference Call to be Held Today, Friday, May 5, 2017 at 8:30am ET NEW YORK, May 05, 2017 — TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the first quarter ended March 31, 2017 and recent company developments. Michael S. Weiss, the Company’s … Continue reading


Fortress Biotech Announces Final Patient Dosed in Phase 1B Trial of CAEL-101 for the Treatment of AL Amyloidosis

CAEL-101 is in development by Fortress subsidiary Caelum Biosciences Preliminary Phase 1b data expected mid-2017; full data readout anticipated in late 2017 Phase 2 study planned for the first half of 2018 NEW YORK, May 04, 2017 — Fortress Biotech, … Continue reading


MOTIF BIO REPORTS YEAR-END 2016 FINANCIAL RESULTS

NEW YORK, May 01, 2017— Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced financial results for the year ended December 31, 2016. “Motif Bio made significant progress in 2016 towards our goal of bringing our … Continue reading


VERASTEM APPOINTS ERIC K. ROWINSKY TO THE BOARD OF DIRECTORS

BOSTON May 2, 2017— Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of Eric K. Rowinsky, MD to its Board of Directors. Dr. Rowinsky brings to Verastem nearly 30 years … Continue reading


Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-102 SL Composition and Formulation: Designed for Transmucosal Absorption and Bedtime Daily Use

TNX-102 SL is an FDA-Designated Breakthrough Therapy for PTSD in Phase 3 Development NEW YORK, May 02, 2017  — Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, announced today the issuance … Continue reading


TG Therapeutics Announces Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the American Academy of Neurology 69th Annual Meeting

MS patients treated with TG-1101 exhibited median B-cell depletion of 99% at week 4 TG-1101 was well tolerated with no grade 3/4 adverse events reported, with median time on study of 5 months NEW YORK, April 28, 2017 — TG Therapeutics, Inc. (NASDAQ:TGTX) today … Continue reading


Checkpoint Therapeutics to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.

NEW YORK, April 27, 2017 — Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT), a Fortress Biotech (FBIO) company, today announced that James F. Oliviero, President and CEO of Checkpoint, will present a company update at PIONEERS 2017, presented by Joseph Gunnar & … Continue reading


Fortress Biotech to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.

NEW YORK, April 27, 2017 — Fortress Biotech, Inc. (FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that Lindsay A. Rosenwald, M.D., Fortress Biotech’s Chairman, President and CEO, will present … Continue reading


TG Therapeutics, Inc. Recaps Schedule of Data Presentation at the Upcoming American Academy of Neurology 69th Annual Meeting

NEW YORK, April 24, 2017 — TG Therapeutics, Inc. (NASDAQ:TGTX), today recapped the presentation schedule for TG-1101 (ublituximab), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, at the upcoming 69th American Academy of Neurology (AAN) annual meeting, to be held April 22-28, 2017, in Boston, MA. The presentation details … Continue reading


TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology

Positive results from the GENUINE Phase 3 study to be featured in an oral presentation NEW YORK, April 20, 2017 — TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that clinical abstracts featuring TG-1101 and TGR-1202 have been selected for presentation at the upcoming 53rd Annual Meeting of … Continue reading


Motif Bio Announces Positive Results for Iclaprim, in the REVIVE-1 Phase 3 Study

Iclaprim met the primary endpoint Iclaprim was well tolerated in the study Data from the second Phase 3 ABSSSI Trial, REVIVE-2, expected in the second half of 2017 NDA submission expected in the first half of 2018 Company to host … Continue reading